Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.

被引：6

作者：

Klempner, Samuel J.

Lee, Keun-Wook

Metges, Jean-Philippe

Catenacci, Daniel V. T.

Loupakis, Fotios

Ilson, David H.

Shah, Manish A.

Shitara, Kohei

Arozullah, Ahsan

Park, Jung Wook

Raizer, Jeffrey J.

Bang, Yung-Jue

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[3] Hop Morvan, Ctr Hosp Reg Univ Brest, Brest, France

[4] Univ Chicago, Gastrointestinal Oncol Program, Chicago, IL 60637 USA

[5] Univ Azienda Osped Univ Pisana, Pisa, Italy

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Weill Cornell Med Coll, New York, NY USA

[8] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[9] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[10] Seoul Natl Univ, Coll Med, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e16063

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16063

引用

页数：3

共 50 条

[41] MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction
Cunningham, David
Bang, Yung-Jue
Tabernero, Josep
Shah, Manish A.
Lordick, Florian
Hack, Stephen Paul
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[42] Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
Park, Wungki
O'Reilly, Eileen Mary
Furuse, Junji
Li, Chung-Pin
Oh, Do-Youn
Garcia-Carbonero, Rocio
Roth, Gael
Lee, Ho-Jin
Bhattacharya, Pranob P.
Moran, Diarmuid Martin
Yang, Jianning
Kunieda, Futoshi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS782 - TPS782
[43] NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Cecchini, Michael
LoRusso, Patricia
Shyr, Yu
Ivy, S. Percy
Sklar, Jeffrey
Dooley, Kirsten
Lacy, Jill
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[44] Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
Tabernero, Josep
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles S.
Janjigian, Yelena Y.
Bhagia, Pooja
Li Kan
Adelberg, David E.
Kui, Qin Shu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[45] Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).
Bang, Yung-Jue
Golan, Talia
Lin, Chia-Chi
Kang, Yoon-Koo
Wainberg, Zev A.
Wasserstrom, Heather
Jin, Jin
Mi, Gu
McNeely, Samuel
Laing, Naomi
Goff, Laura Williams
Fu, Siqing
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[46] Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Pinto, C.
Di Fabio, F.
Barone, C.
Siena, S.
Falcone, A.
Cascinu, S.
Rojas, Llimpe F.
Artale, S.
Schinzari, G.
Giaquinta, S.
Mutri, V
Martoni, A.
ANNALS OF ONCOLOGY, 2008, 19 : 9 - 9
[47] A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
Menglong Zhou
Wang Yang
Yan Xuan
Wei Zou
Yaqi Wang
Zhiyuan Zhang
Jing Zhang
Miao Mo
Changming Zhou
Yuan Liu
Wenming Zhang
Zhaozhen Zhang
Yiping He
Weiwei Weng
Cong Tan
Lei Wang
Dan Huang
Weiqi Sheng
Huanhuan Li
Hui Zhu
Yan Wang
Lijun Shen
Hui Zhang
Juefeng Wan
Guichao Li
Hua Huang
Yanong Wang
Zhen Zhang
Xiaowen Liu
Fan Xia
BMC Cancer, 22
[48] A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study
Zhou, Menglong
Yang, Wang
Xuan, Yan
Zou, Wei
Wang, Yaqi
Zhang, Zhiyuan
Zhang, Jing
Mo, Miao
Zhou, Changming
Liu, Yuan
Zhang, Wenming
Zhang, Zhaozhen
He, Yiping
Weng, Weiwei
Tan, Cong
Wang, Lei
Huang, Dan
Sheng, Weiqi
Li, Huanhuan
Zhu, Hui
Wang, Yan
Shen, Lijun
Zhang, Hui
Wan, Juefeng
Li, Guichao
Huang, Hua
Wang, Yanong
Zhang, Zhen
Liu, Xiaowen
Xia, Fan
BMC CANCER, 2022, 22 (01)
[49] Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis
Kang, Yoon-Koo
Qin, Shukui
Lee, Keun-Wook
Oh, Sang Cheul
Kim, In-Ho
Kim, Jong Gwang
Li, Yong
Yan, Zhuchen
Li, Jin
Bai, Li-Yuan
Chan, Catherine
Yusuf, Akeem
Zahlten-Kuemeli, Anita
Taylor, Kate
Yamaguchi, Kensei
GASTRIC CANCER, 2024, 27 (05) : 1046 - 1057
[50] A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Gutierrez, Martin
Sigal, Darren
Berth, Kevin
Kuehn, Adam
Colerangle, John
Koppisetti, Sharmila
He, Shawn
van der Touw, William
Hariri, Robert
Awadalla, Mark S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS478 - TPS478

← 1 2 3 4 5 →